Abstract 2358P
Background
Robotic total gastrectomy (RTG) is accepted as a safety approach to conventional laparoscopy total gastrectomy (LTG) for locally advanced gastric cancer. However, the long-term oncological efficacy of RTG remains unclear.
Methods
This prospective study included 48 patients with advanced proximal GC underwent RTG combined with spleen-preserving splenic hilar lymphadenectomy between March 2018 and February 2020. Patients who underwent LTG in the FUGES-002 study were enrolled in a 1:2 ratio to compare the outcomes between RTG and LTG. The primary outcome was overall postoperative morbidity rate. The secondary outcomes were three-year overall survival (OS), three-year disease-free survival (DFS), and recurrence patterns.
Results
After 1:2 propensity score matching, a total of 48 RTG and 96 LTG patients were included, with similar clinical and pathological data in both groups. In terms of surgical outcomes, the RTG group had significantly less intraoperative bleeding than the LTG group (66.4 vs. 38.7 ml, P = 0.042). With regard to lymph node dissection, the RTG group had a significantly higher number of non-gastric lymph node dissections than the LTG group (20.2 vs. 17.5, P = 0.039), and its lymph node metastasis rate was significantly lower than that of the LTG group (27.1% vs. 45.8%, P = 0.030); in terms of postoperative outcomes, the RTG group had significantly shorter times for first gas discharge, first out of bed, first liquid diet, first semi-liquid diet, and length of stay than the LTG group (P <0.05). Regarding long-term prognosis, the 3-year DFS of the RTG and LTG groups were 77.1% and 68.8%, respectively, and the 3-year OS were 85.4% and 74.0% (P >0.05 for both). Within 3 years after surgery, 9 (18.8%) and 27 (28.1%) patients in the RTG and LTG groups experienced recurrence, respectively, with similar recurrence patterns in both groups (P >0.05). There was no independent correlation between RTG and recurrence or gastric cancer-specific death (P >0.05 for both).
Conclusions
Among patients with a preoperative clinical stage indicating locally advanced gastric cancer, RTG, compared with LTG, did not result in inferior disease-free survival and overall survival at 3 years.
Clinical trial identification
The FUGES-014 was a prospective, single-arm, open-label study (NCT03524287) that was conducted at Fujian Medical University Union Hospital (FMUUH).
Editorial acknowledgement
Legal entity responsible for the study
Changming Huang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16
2347P - Correlation between second primary cancers and first primary cancers: A systematic review and meta-analysis of 9 million cancer patients
Presenter: Xinyu Wang
Session: Poster session 16
2348P - High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma
Presenter: hongfang zhang
Session: Poster session 16
2349P - Patterns and frequency of pathogenic germline variants (PGVs) among non-western young male patients with cancer: The Jordanian exploratory cancer genetics (Jo-ECAG) study
Presenter: Hira Bani Hani
Session: Poster session 16
2350P - Single-cell RNA-seq dissecting the initiating liver metastasis cells in various cancers
Presenter: Shu-yue Zheng
Session: Poster session 16
2351P - Whole genome sequencing of AYA patients
Presenter: Paul Roepman
Session: Poster session 16
2352P - Sex-based differences in genomic alterations and biomarkers in anal squamous cell carcinoma (ASCC)
Presenter: Stefano Cereda
Session: Poster session 16
2353P - Anti-cancer effects of HDAC8 specific inhibitors EC-352H and EC-374H in lymphoma
Presenter: So Young Lee
Session: Poster session 16
2354P - Computational pathology-derived features capture varied epithelial-mesenchymal transition (EMT) states
Presenter: Herbert Levine
Session: Poster session 16
2355P - Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors
Presenter: Kristina Jansen
Session: Poster session 16